{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:29:55Z","timestamp":1785428995013,"version":"3.56.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:p>Ocrelizumab, a humanized anti-CD20 monoclonal antibody approved for multiple sclerosis in 2017, modulates B-cell activity to reduce disease progression. While clinical trials demonstrate its efficacy, real-world safety data remain critical to identify rare or long-term adverse events (AEs) not captured in controlled studies. This study analyzed post-marketing AEs of ocrelizumab using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) to assess safety under real-world conditions. A retrospective pharmacovigilance analysis was conducted on FAERS data from Q1 2017 to Q4 2023. Disproportionality analyses including reporting odds ratio, proportional reporting ratio, Bayesian Confidence Propagation Neural Network, and Multi-item Gamma Poisson Shrinker were used to detect safety signals. Subgroup, sensitivity, and time-to-onset analyses further characterized AE profiles. Among 50,967 reports, the analysis confirmed several AEs consistent with the ocrelizumab prescribing information, including urinary tract infection, depression, cough, herpes zoster, and breast cancer. Furthermore, potential new safety signals not previously documented in the drug\u2019s label were identified, such as alopecia, insomnia, weight increased, and sepsis. This study confirms known AEs and identifies unexpected AEs, emphasizing the need for targeted monitoring, particularly during early therapy. Real-world FAERS data complement trial findings, aiding clinicians in optimizing multiple sclerosis treatment strategies.<\/jats:p>","DOI":"10.1097\/md.0000000000044883","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:07:40Z","timestamp":1759781260000},"page":"e44883","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["A retrospective pharmacovigilance study of ocrelizumab in multiple sclerosis: Analysis of the FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.1097","volume":"104","author":[{"given":"Hong-Yan","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shenzhen Longhua District Central Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Bin","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai East Hospital, Tongji University, Shaghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0232-0821","authenticated-orcid":false,"given":"Pei-Jie","family":"Ye","sequence":"additional","affiliation":[{"name":"Jiyang College, Zhejiang Agriculture and Forestry University, Shaoxing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai East Hospital, Tongji University, Shaghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260526","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis.","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"R2-20260526","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis.","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"R3-20260526","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis.","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20260526","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1474-4422(14)70041-9","article-title":"Multiple sclerosis genetics.","volume":"13","author":"Sawcer","year":"2014","journal-title":"Lancet Neurol"},{"issue":"sup2","key":"R5-20260526","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1586\/14737175.2013.865866","article-title":"Environmental factors in multiple sclerosis.","volume":"13","author":"Ascherio","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"R6-20260526","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis.","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"R7-20260526","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1191\/1352458503ms965oa","article-title":"Blood-brain barrier disruption in multiple sclerosis.","volume":"9","author":"Ortiz","year":"2003","journal-title":"Mult Scler"},{"key":"R8-20260526","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis.","volume":"9","author":"Lassmann","year":"2019","journal-title":"Front Immunol"},{"key":"R9-20260526","doi-asserted-by":"crossref","first-page":"101427","DOI":"10.1016\/j.msard.2019.101427","article-title":"The multiple sclerosis gut microbiota: a systematic review.","volume":"37","author":"Mirza","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R10-20260526","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"key":"R11-20260526","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"R12-20260526","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis.","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"R13-20260526","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis.","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"R14-20260526","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?.\u201d.","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"R15-20260526","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00415-025-13224-8","article-title":"Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study.","volume":"272","author":"Zaccone","year":"2025","journal-title":"J Neurol"},{"key":"R16-20260526","doi-asserted-by":"crossref","first-page":"e210142","DOI":"10.1212\/WNL.0000000000210142","article-title":"Long-term treatment with ocrelizumab in patients with early-stage relapsing MS: nine-year data from the OPERA studies open-label extension.","volume":"104","author":"Cerqueira","year":"2025","journal-title":"Neurology"},{"key":"R17-20260526","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s13760-024-02572-3","article-title":"Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up.","volume":"124","author":"Erdogan","year":"2024","journal-title":"Acta Neurol Belg"},{"key":"R18-20260526","doi-asserted-by":"crossref","first-page":"e213574","DOI":"10.1212\/WNL.0000000000213574","article-title":"Subcutaneous ocrelizumab in patients with multiple sclerosis: results of the phase 3 OCARINA II study.","volume":"104","author":"Newsome","year":"2025","journal-title":"Neurology"},{"key":"R19-20260526","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/acn3.51732","article-title":"Real-world evaluation of ocrelizumab in multiple sclerosis: a systematic review.","volume":"10","author":"Montalban","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"R20-20260526","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jbi.2015.02.004","article-title":"Utilizing social media data for pharmacovigilance: a review.","volume":"54","author":"Sarker","year":"2015","journal-title":"J Biomed Inform"},{"key":"R21-20260526","doi-asserted-by":"crossref","first-page":"104015","DOI":"10.1016\/j.msard.2022.104015","article-title":"Ocrelizumab-related neutropenia: effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS).","volume":"65","author":"Hammer","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"R22-20260526","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1177\/1352458520949986","article-title":"Adverse event profile differences between rituximab and ocrelizumab: findings from the FDA Adverse Event Reporting Database.","volume":"27","author":"Caldito","year":"2021","journal-title":"Mult Scler"},{"key":"R23-20260526","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/13524585231195854","article-title":"Immune-mediated colitis associated with ocrelizumab: a new safety risk.","volume":"29","author":"Kim","year":"2023","journal-title":"Mult Scler"},{"key":"R24-20260526","doi-asserted-by":"crossref","first-page":"JITC17","DOI":"10.7326\/IsTranslatedFrom_AITC201808070_Japanese","article-title":"Herpes zoster (Japanese Version).","volume":"169","author":"Schmader","year":"2018","journal-title":"Ann Intern Med"},{"key":"R25-20260526","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1474-4422(08)70192-3","article-title":"B cells and multiple sclerosis.","volume":"7","author":"Franciotta","year":"2008","journal-title":"Lancet Neurol"},{"key":"R26-20260526","first-page":"1245","article-title":"B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application.","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol"},{"key":"R27-20260526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/11795735211037785","article-title":"Breast carcinoma after ocrelizumab therapy in multiple sclerosis patients: a case series and literature review.","volume":"13","author":"Kelsey","year":"2021","journal-title":"J Cent Nerv Syst Dis"},{"key":"R28-20260526","doi-asserted-by":"crossref","first-page":"497041","DOI":"10.3389\/fimmu.2019.02954","article-title":"Multiple sclerosis and cancer: the Ying-Yang effect of disease modifying therapies.","volume":"10","author":"Melamed","year":"2020","journal-title":"Front Immunol"},{"key":"R29-20260526","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1164\/rccm.201504-0781OC","article-title":"Assessment of global incidence and mortality of hospital-treated sepsis: current estimates and limitations.","volume":"193","author":"Fleischmann","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"R30-20260526","doi-asserted-by":"crossref","first-page":"967017","DOI":"10.3389\/fphar.2022.967017","article-title":"Do antibody\u2013drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study.","volume":"13","author":"Xia","year":"2022","journal-title":"Front Pharmacol"},{"key":"R31-20260526","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis.","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"key":"R32-20260526","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s15010-025-02479-y","article-title":"Echovirus serotype 11 induced sepsis in a young female patient with multiple sclerosis treated with anti-CD20 monoclonal antibody ocrelizumab.","volume":"53","author":"Starosta","year":"2025","journal-title":"Infection"},{"key":"R33-20260526","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s13555-022-00864-1","article-title":"The association of alopecia areata-related emotional symptoms with work productivity and daily activity among patients with alopecia areata.","volume":"13","author":"Gandhi","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R34-20260526","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40257-018-0405-2","article-title":"The medical and psychosocial associations of alopecia: recognizing hair loss as more than a cosmetic concern.","volume":"20","author":"Marks","year":"2019","journal-title":"Am J Clin Dermatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:27:17Z","timestamp":1779805637000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":34,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044883","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"2025-06-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}